Region-specific distribution of β-amyloid peptide and cytokine expression in TgCRND8 mice

Neuroscience Letters

Volumn 492, Issue 1, 2011, Pages 5-10

  Ma, Keran ^a,b   Mount, Howard T J ^a,b   McLaurin, JoAnne ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Beta amyloid peptide; CXCL1; IL 1 ; TgCRND8

Indexed keywords

AMYLOID BETA PROTEIN; CXCL1 CHEMOKINE; CYTOKINE; INTERLEUKIN 1BETA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; MOUSE; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE;

AGE FACTORS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHEMOKINE CXCL1; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-1BETA; MALE; MICE; MICE, TRANSGENIC;

EID: 79952007732     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.035     Document Type: Article

References (28)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159.
3. Bayer T.A., Wirths O. Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci. 2010, 2:1-10.
4. Bellucci A., Laccarini I., Scali C., Prosperi C., Gioyannini M.G., Pepeu G., Casamenti F. Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol. Dis. 2006, 23:260-272.
5. Braak H., Braak E., Bohl J., Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J. Neurol. Sci. 1989, 93:277-287.
6. Butler M.P., O'Connor J.J., Moynagh P.N. Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 2004, 124:319-326.
7. Chishti A.M., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 274:21562-21570.
8. Christen-Zaech S., Kraftsik R., Pillevuit O., Kiraly M., Martins R., Khalili K., Miklossy J. Early olfactory involvement in Alzheimer's disease. Can. J. Neurol. Sci. 2003, 30:20-25.
9. Golde T.E., Eckman C.B., Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis,and treatment of Alzheimer's disease. Biochem. Biophys. Acta 2000, 1502:172-187.
10. Goldgaber D., Harris H.W., Hla Y., Maciag T., Donnelly R.J., Jacobsen J.S., Vitek M.P., Carleton G. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. PNAS 1989, 86:7606-7610.
11. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 279:353-356.
12. Hickman S.E., Allison E.K., Khoury J.L. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease Mice. J. Neurosci. 2008, 28:8354-8360.
13. Jimenez S., Baglietto-Vargas D., Caballero C., Moreno-Gonzalez I., Torres M., Sanchez-Varo R., Ruano D., Vizuete M., Gutierrez A., Vitorica J. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 2008, 28:11650-11661.
14. Joachim C.L., Morris J.H., Selkoe D.J. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am. J. Pathol. 1989, 135:309-319.
15. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
16. Klein W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
17. Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
18. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
19. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U., Kornhuber J., Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25:273-281.
20. Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., Wolfe M.S. Tumor necrosis factor-α, interleukin-1β, and interferon-γ stimulate γ-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 2004, 279:49523-49532.
21. Matyash V., Kettenmann H. Heterogeneity in astrocyte morphology and physiology. Brain Res. Rev. 2010, 63:2-10.
22. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12:801-808.
23. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
24. Peng S., Garzon D.J., Marchese M., Klein W., Ginsberg S.D., Francis B.M., Mount H.T.J., Mufson E.J., Salehi A., Fahnestock M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J. Neurosci. 2009, 29:9321-9329.
25. Thal D.R., Rüb U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
26. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572:477-492.
27. Vandenabeele P., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?. Immunol. Today 1991, 12:217-219.
28. Yang H.T., Cohen P., Rousseau S. IL-1beta-stimulated activation of ERK1/2 and p38alpha MAPK mediates the transcriptional up-regulation of IL-6, IL-8 and GRO-alpha in HeLa cells. Cell. Signal. 2008, 20:375-380.